Replimune (REPL) Cash from Financing Activities (2018 - 2026)
Replimune (REPL) posted Cash from Financing Activities of $55.7 million for Q1 2026, up 432.74% sequentially from $10.5 million in Q4 2025, and up 42279.55% YoY from N/an in Q1 2025.
Replimune (REPL) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Replimune has reported Cash from Financing Activities for 9 years, with the latest figure at $55.7 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 42279.55% year-over-year to $55.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $66.3 million (down 73.73% YoY) and the FY2026 annual result came in at $66.3 million, down 73.73% from the prior year.
- Cash from Financing Activities advanced to $55.7 million in Q1 2026 per REPL's latest filing, from $10.5 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $271.4 million in Q4 2022 and troughed at -$158000.0 in Q2 2025.
- A 5-year average of $38.0 million and a median of $1.1 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 121.45% in 2023, then surged 42279.55% in 2026.
- Over 5 years, Cash from Financing Activities stood at $271.4 million in 2022, then sank by 94.52% to $14.9 million in 2023, then soared by 948.62% to $155.9 million in 2024, then tumbled by 93.3% to $10.5 million in 2025, then soared by 432.74% to $55.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $55.7 million, $10.5 million, and $324000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Replimune | 1.24 Bn | 1.24 Bn | - | 55.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 55.68 Mn |
| Mar 31, 2026 | 55.68 Mn |
| Dec 31, 2025 | 10.45 Mn |
| Dec 31, 2025 | 10.45 Mn |
| Sep 30, 2025 | 324,000.00 |
| Sep 30, 2025 | 324,000.00 |
| Jun 30, 2025 | -158,000.00 |
| Jun 30, 2025 | -158,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Mar 31, 2025 | -132,000.00 |
| Dec 31, 2024 | 155.93 Mn |
| Dec 31, 2024 | 155.93 Mn |
| Sep 30, 2024 | -39,000.00 |
| Sep 30, 2024 | -39,000.00 |
| Jun 30, 2024 | 96.64 Mn |
| Jun 30, 2024 | 96.64 Mn |
| Mar 31, 2024 | -130,000.00 |
| Mar 31, 2024 | -130,000.00 |
| Dec 31, 2023 | 14.87 Mn |
| Dec 31, 2023 | 14.87 Mn |